Renal Hemodynamic and Natriuretic Effects of Concomitant Angiotensin-Converting Enzyme and Neutral Endopeptidase Inhibition in Men

@article{Regamey2002RenalHA,
  title={Renal Hemodynamic and Natriuretic Effects of Concomitant Angiotensin-Converting Enzyme and Neutral Endopeptidase Inhibition in Men},
  author={F. Regamey and M. Maillard and J. Nussberger and H. Brunner and M. Burnier},
  journal={Hypertension: Journal of the American Heart Association},
  year={2002},
  volume={40},
  pages={266-272}
}
  • F. Regamey, M. Maillard, +2 authors M. Burnier
  • Published 2002
  • Medicine
  • Hypertension: Journal of the American Heart Association
  • This double-blind placebo-controlled study was designed to investigate the acute and sustained hormonal, renal hemodynamic, and tubular effects of concomitant ACE and neutral endopeptidase (NEP) inhibition by omapatrilat, a vasopeptidase inhibitor, in men. Thirty-two normotensive subjects were randomized to receive a placebo, omapatrilat (40 or 80 mg), or the fosinopril/hydrochlorothiazide (FOS/HCTZ; 20 and 12.5 mg, respectively) fixed combination for 1 week. Blood pressure, renal hemodynamics… CONTINUE READING
    30 Citations
    Combined neutral endopeptidase inhibitors
    • 24
    Antianginal efficacy of omapatrilat in patients with chronic angina pectoris.
    • 14
    The future of angiotensin II inhibition in cardiovascular medicine.
    • 23

    References

    SHOWING 1-10 OF 30 REFERENCES
    Effects of SCH 34826, an orally active inhibitor of atrial natriuretic peptide degradation, in healthy volunteers
    • 18